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Correspondence Statin Therapy Does Not Attenuate
Exercise Training Response in
Cardiac RehabilitationTo the Editor: HMG co-reductase inhibitors (statins) lower car-
diovascular events in patients with coronary heart disease (CHD).
Beyond lipid effects, statins provide beneﬁts through effects on
inﬂammation, the renin-angiotensin system, endothelial function,
and arterial compliance. However, statin use is associated with
myalgia and fatigue. Furthermore, Mikus et al. (1) reported that
simvastatin attenuated aerobic training in statin-naïve, over-
weight subjects at risk for metabolic syndrome during a 12-week
exercise program similar to that used in cardiac rehabilitation
(CR). This ﬁnding is concerning for CR populations, as baseline
aerobic capacity (VO2peak) and improvements after participation
are correlated with reductions in cardiovascular disease–related
and all-cause mortality (2). Additionally, exercise in conjunction
with statin therapy lowers mortality in hyperlipidemic patients
more than either therapy alone (3). Given the prevalence of statin
treatment among patients undergoing CR, we sought to deter-
mine whether its use attenuates the exercise-training response,
measured directly by VO2peak (ml O2/kg/min) in CR patients with
CHD.
Study data were prospectively collected from January 1996 to
July 2013 and included those from patients after an acute CHD
event who performed both CR entry and exit exercise-tolerance
tests with expired-gas analysis. The cohort was divided into two
groups on the basis of statin use throughout the CR program. Each
patient completed an exercise program of 3 sessions/week for
36 sessions.
Of 5,750 patients, 1,201 with CHD met study criteria over the
review period, including 968 (81%) in the statin group and 233
(19%) in the nonstatin group. The percentage of patients taking
statins over the study period increased from 56% during 1996–
1998, to 80% throughout 2003–2005, and ﬁnally to 94% within
2010–2012 (p < 0.0001 for trend). Groups were similar by sex.
The nonstatin group began CR later after hospital discharge, and
had lower body weight, body mass index, VO2peak, handgrip
strength, and self-reported physical ﬁtness, but higher depression
scores. The statin group had signiﬁcantly lower total cholesterol
and low-density lipoprotein cholesterol levels, evincing adherence
to the medication (Table 1). Smoking status and rates of type 2
diabetes mellitus did not differ.
Adherence to exercise training was similar between groups
(mean  SD: 26  10 sessions vs. 26  9 sessions; p ¼ 0.97).
VO2peak increased similarly after exercise training in both study
groups when expressed per body mass (p ¼ 0.73) or in absolute
terms (in l O2/min) (p ¼ 0.84) (Table 1). Furthermore, changes in
handgrip strength, self-reported depression, and physical function
scores were similar between groups.
For patients with a surgical diagnosis (coronary artery bypass
grafting), 392 (76%) were taking statins versus 122 not taking
statins. The increase in VO2peak was similar in these two subgroups(mean  SD: þ4.0  3.9 ml O2/kg/min vs. þ3.8  3.6 ml
O2/kg/min; p ¼ 0.74).
Within the statin group, men had a higher baseline VO2peak
(mean  SD: 20.6  6.6 ml O2/kg/min vs. 15.6  4.4 ml
O2/kg/min; p < 0.0001) and a greater increase with training
(mean  SD: 19.4  21.8% vs. 13.1  20.8%; p < 0.0001)
compared with those in women, although differences were
consistent across statin status (p ¼ NS).
In view of a recent study documenting attenuated exercise
training in overweight patients taking statin medications (1), we
assessed whether statin use blunts exercise training in patients with
CHD participating in CR. In contrast, our analysis demonstrates
no effect of statins on the exercise-induced improvement in
VO2peak during CR. Furthermore, our results demonstrate an
improved VO2peak in the range of previously reported values.
Because the exercise-training response to CR is linked to im-
provements in prognosis (2), our ﬁndings have relevance to
>250,000 patients participating in CR annually in the United
States.
The study by Mikus et al. (1) was limited by not comparing pre-
training, on-statin exercise-test status to pre-statin status to assess
the acute effect of statins on exercise performance prior to training.
Therefore, their results may be explained by an acute reduction in
VO2peak, whereas both groups could have trained similarly. Addi-
tionally, Mikus et al. (1) did not include a placebo group (4).
The nonstatin group in our study consisted of 52% surgical
patients versus 40% in the statin group. Although our data
documented baseline differences by statin status in ﬁtness,
strength, physical function, and depression scores, the baseline
differences were likely due to higher rates of surgical recovery in
the nonstatin group versus the medically treated patients, not
statin use per se. However, the primary goal of the study, to
investigate training-induced improvements in ﬁtness on or off
statin treatment, is less in doubt, as the training response between
groups was identical. Although the proportion of men to women
differed between groups, this is consistent with national CR
enrollment, and the effects of training in patients of both sexes
receiving statin medications were within the range of previously
reported values.
The primary strength of our study was the investigation of the
effect of statin use on exercise-training adaptations, assessed by
changes in VO2peak directly measured by gas analysis rather than
estimated by treadmill time, in a large cohort of CHD patients.
Additionally, we analyzed multiple clinical variables, including
baseline strength, ﬁtness, and body mass index. Limitations
included nonrandomized analysis of predominantly Caucasian pa-
tients from a single clinical center. Second, data on underlying
musculoskeletal conditions that might have affected exercise ability
were not available. Third, we did not measure the acute effects of




(n ¼ 233) p Value
Baseline characteristics
Age, yrs 64  10 66  11 <0.01
Sex 0.06
Male 761 (79) 170 (73) –
Female 207 (21) 63 (27) –
Time since event, days 36  21 42  20 <0.0001
Weight, kg 85  17 82  17 <0.01
BMI, kg/m2 29.1  5.1 27.9  5.0 0.001
VO2peak, ml O2/kg/min 19.5  6.5 18.0  6.1 0.001
Peak RER, VCO2/VO2 1.09  0.12 1.05  0.11 <0.0001
Handgrip strength, kg 36  11 33  11 0.001
MOS SF-36 Physical Function subscale score 65  26 59  25 0.003
Geriatric depression score* 2.8  2.8 3.4  2.8 <0.01
Total cholesterol, mg/dl 161  38 181  42 <0.0001
LDL cholesterol, mg/dl 91  32 107  35 <0.0001
Index diagnosis
CABG 392 (41) 122 (52) 0.001
Myocardial infarction 312 (32) 64 (28) 0.16
PCI 250 (26) 37 (16) 0.001
Medical therapy/stable angina 13 (1) 10 (4) <0.01
Exercise-induced changes
Weight, kg –1.1  3.9y –0.7  3.3y 0.16
VO2peak, ml O2/kg/min þ3.2  3.7y þ3.1  3.7y 0.73
VO2peak, l O2/min þ0.25  0.31y þ0.24  0.32y 0.84
Handgrip strength, kg þ1.7  4.5y þ1.3  4.1y 0.27
MOS SF-36 Physical Function subscale score þ19  23y þ22  22y 0.06
Geriatric depression score* –1.2  2.4y –1.5  2.4y 0.09
Values are mean  SD or n (%). *Depression score >5 demonstrates signiﬁcant symptoms of depression. yWithin-group signiﬁcant difference from
baseline at p < 0.01.
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; LDL ¼ low-density lipoprotein; MOS SF-36 ¼ Medical Outcomes Study 36-item
Short Form; PCI ¼ percutaneous coronary intervention; RER ¼ respiratory exchange ratio; VCO2 ¼ carbon dioxide production; VO2 ¼ oxygen
consumption; VO2peak ¼ peak aerobic capacity.
JACC Vol. 63, No. 19, 2014 Correspondence
May 20, 2014:2050–5
2051statin use. Finally, within the statin group, we did not have data to
verify the type and dosage of medication, and the length of statin
use ranged from 1 month to multiple years as we had data only on
whether patients were taking or not taking a statin medication
during the training period. Nonetheless, our results clearly
demonstrate that long-term statin use does not attenuate aerobic
training effects in CR patients and that the expected survival
beneﬁts of CR are expected, indeed, to persist.Jason L. Rengo, MSy
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